Is Panbela Therapeutics, Inc. overvalued or undervalued?

As of 15 October 2023, Panbela Therapeutics, Inc. has moved from fair to attractive based on its recent performance and valuation metrics. The company appears to be undervalued at this time. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, indicating a solid financial position relative to its market value.
In comparison to peers, such as OncoSec Medical Incorporated with a price-to-earnings ratio of 15.0 and ImmunoGen, Inc. at 14.2, Panbela's valuation suggests it is trading at a discount. This relative undervaluation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the positive outlook for the company's future growth potential.